Featured NewsUp one level
Is nanomedicine the next big thing? A growing number of top drug companies seem to think so.
After an interview with its previous chairman last year, the ETPN continues to contribute to the European research report called International Innovation. The article written by the ETPN secretariat is to be published as the last word of the June 2013 issue and is presenting the potential of nanotechnologies in healthcare.
AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins™
BIND Eligible to Receive Approximately $50 Million in Upfront and Development Milestone Payments Plus Additional Regulatory and Sales Milestones and Royalties for Each Accurin
Nanonica, a company focusing on added value transforming ideas into marketable products, has just launched a Nanotechnology Prize initiative. The award has two categories: 1.- Breakthrough of the year: chosen by a scientific committee (10000 €) 2.- Best applied proposal: to be submitted by the 30th of August 2013
The event "Advanced Summer School Interrogations at the Biointerface - Inflammation/Repair Interface", takes place in Porto, Portugal, from the 25th to the 28th of June 2013.